Person: CENGİZ, MURAT
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
CENGİZ
First Name
MURAT
Name
5 results
Search Results
Now showing 1 - 5 of 5
Publication A novel β-lactam-aminoglycoside combination in veterinary medicine: The couse of ceftiofur and gentamicin to combat resistant Escherichia coli(Hellenic Veterinary Medical Society, 2020-04-01) Cengiz, M.; Şahintürk, P.; Hepbostancı, G.; Akalın, H.; Sonal, S.; CENGİZ, MURAT; ŞAHİNTÜRK, SERDAR; AKALIN, EMİN HALİS; SONAL, SONGÜL; HEPBOSTANCI, G.; Bursa Uludağ Üniversitesi/Veteriner Fakültesi.; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Enstitüsü.; 0000-0001-7530-1279; AAU-8952-2020; ABE-5935-2020The focus of this study was to evaluate the efficacy of ceftiofur+gentamicin combination to increase the success of antimicrobial inhibition against resistant Escherichia coli (E.coli) strains isolated from animals. Interaction between drugs was determined using checkerboard method and the fractional inhibitory concentration index was interpreted as synergism, antagonism and indifference. The combination was defined as bactericidal or bacteriostatic based on the minimum bactericidal test results. Mutant prevention concentration test was used to evaluate the resistance tendency suppression potential of the combination. The synergistic effect was detected for all E. coli strains by the checkerboard method; even the strains that were resistant to the individual compounds in the combination. Based on the results of minimum bactericidal concentration test, the combination exhibited bactericidal effect against all E. coli strains. In addition, the individual mutant prevention concentrations of ceftiofur and gentamicin decreased up to 125-fold by using the combination for the inhibition of resistant E. coli strains. The results indicated that killing potential of co-use of the compounds is much stronger than their individual use. The combination achieved to decrease the mutant prevention concentrations and this can reduce the risk of emergence of single mutations during treatment done with suggested doses.Publication The in vitro activity of danofloxacin plus ceftiofur combination: Implications for antimicrobial efficacy and resistance prevention(Urmia Univ, 2022-03-01) Cengiz, Murat; CENGİZ, MURAT; Şahintürk, Pınar; Hepbostancı, Gülce; Akalın, Halis; AKALIN, EMİN HALİS; Sonal, Songül; SONAL, SONGÜL; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Klinik Mikrobiyoloji Anabilim Dalı.; 0000-0001-7530-1279; ABE-5935-2020; AAU-8952-2020Due to the high prevalence of multi-drug resistant bacteria, combination therapy is an efficient choice for treatment of infections caused by highly resistant strains. In this study, the efficacy of ceftiofur plus danofloxacin combination was investigated against resistant Escherichia coli. The interaction between the two drugs was determined by checkerboard tests and time-kill assays. The combination was defined as bactericidal or bacteriostatic based on the minimum bactericidal concentration test results. Mutant prevention concentration test was used to evaluate the resistance tendency suppression potential of the combination. The combination had a synergistic effect against 83.00% of the isolates as verified by the checkerboard and time-kill assays. The combination was defined as bactericidal against all E. coli strains, since minimum bactericidal concentration: minimum inhibitory concentration ratios were below four thresholds and also markedly reduced mutant prevention concentration values of ceftiofur up to 4000-fold compared to its single use. Ceftiofur plus danofloxacin combination inhibited growth of E. coli strains which were resistant to ceftiofur or newer generation of fluoroquinolones. Our results suggest that ceftiofur plus danofloxacin combination has a bactericidal characteristic and can be an important alternative for the treatment of infections caused by resistant E. coli.Publication Impact of pH on the activity of co-used antimicrobials against resistant Escherichia coli strains of animal origin(TÜBİTAK, 2020-01-01) Cengiz, Murat; Hepbostancı, Gülce; CENGİZ, MURAT; Hepbostancı, Gülce; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/Farmakoloji ve Toksikoloji Anabilim Dalı/Moleküler Farmakoloji Laboratuvarı.; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Enstitüsü.; ABE-5935-2020; FAV-5978-2022In this study, combination antimicrobial therapy, due to its higher potential against resistant bacteria, was evaluated for the inhibition of multidrug-resistant E. coli strains. The influence of pH as an environmental variable on the activity of antimicrobial combinations was evaluated by calculating the factional concentration indexes at pH values 5.0, 6.0, 7.3, and 8.0.The highest synergistic activity rates of ceftriaxone + colistin, danofloxacin + colistin, danofloxacin + ceftiofur, and ceftiofur + gentamicin combinations were 50%, 33%, 100%, and 50%, respectively measured at >7.3 pH. The lowest synergistic activity rates for all combinations were observed at the acidic pH values of 5.0 and 6.0. The results of this study clearly demonstrated that acidic pH of the medium impaired the activity of the antimicrobial combinations. Although ceftriaxone and ceftiofur exert optimal activity at acidic pH values, the synergistic activity of the co-used drugs reached its highest level at pH >= 7.3.Publication Optimization of culture medium for the production and partial purification and characterization of an antibacterial activity from brevibacillus laterosporus strain EA62(Ars Docendi, 2019-07-01) Usta, Alev A. K.; Demirkan, Elif; Cengiz, Murat; Sevgi, Tuba; Zeren, Behice; Abdou, Maoulida; Usta, Alev A. K.; DEMİRKAN, ELİF; CENGİZ, MURAT; SEVGİ, TUBA; Zeren, Behice; Abdou, Maoulida; Bursa Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü.; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/Farmakoloji ve Toksikoloji Anabilim Dalı.; 0000-0002-5292-9482; ABI-4472-2020; ABE-5935-2020; IPA-7484-2023; ISY-3462-2023; EID-6407-2022; CAU-1487-2022The present study was performed to report the bacterial identification, optimization of culture conditions and characterization of a novel antibiotic substance from a Bacillus sp. EA62 strain isolated from soil. The EA62 strain was identified based on 16S rRNA analysis. The new isolate EBD 9-1 showed 100% sequence identity with Brevibacillus laterosporus. The antibacterial activity of the new substance was examined against five pathogenic bacteria and was observed to be the most effective against Escherichia coli. An agar diffusion assay was performed to evaluate the antibacterial activity of the substance. The effects of some nutritional (amino acid, carbon, nitrogen and metal sources) and physical factors (pH and temperature) and incubation time on the antibiotic activity were studied. Antibiotic activity in basal medium reached the maximum levels after 72 h of incubation. The best antibiotic activity was obtained in the presence of glucose as a carbon source, yeast extract as a nitrogen source, glutamic acid as an amino acid source and MgSO4+CaCO3 as metal ion sources. For physical parameters, the best results were obtained at 37 degrees C, pH 7.0. The antibiotic substance was partially purified, and the estimated molecular weight was 6.3 kDa. The minimum inhibitory concentration (MIC) values determined against five pathogen bacteria were >256 mu g/ml. The substance was identified by thin-layer chromatography, and its Rf value was measured as 0.04 cm.Publication Characterization and prevention of fluoroquinolone resistance in Escherichia coli isolated from animals(Wiley, 2015-07-01) Cengiz, Murat; Şahintürk, Pınar; Sonal, Songül; CENGİZ, MURAT; Şahintürk, Pınar; SONAL, SONGÜL; Uludağ Üniversitesi/Veteriner Fakültesi; 0000-0001-7490-4326; K-3299-2019; ABE-5935-2020; ABI-4237-2020; DPN-8375-2022